Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised,...
Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa
About this item
Full title
Author / Creator
Hughes, D A , Elliott, P M , Shah, J , Zuckerman, J , Coghlan, G , Brookes, J and Mehta, A B
Publisher
London: BMJ Publishing Group Ltd and British Cardiovascular Society
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd and British Cardiovascular Society
Subjects
More information
Scope and Contents
Contents
Background:Anderson–Fabry disease is an X-linked glycosphingolipid storage disorder caused by deficient activity of the lysosomal enzyme α-galactosidase A. This leads to a progressive accumulation of globotriaosylceramide (Gb3) in the lysosomes of cells throughout the body that ultimately results in premature death from renal, cardiac or cerebrovas...
Alternative Titles
Full title
Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_70210225
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_70210225
Other Identifiers
ISSN
1355-6037
E-ISSN
1468-201X
DOI
10.1136/hrt.2006.104026
